We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
Founding partner, Frank Schirripa, said, “We are very pleased to have achieved such a sizable settlement on behalf of cancer patients and our Taft-Hartley Health and Welfare clients who have shouldered the cost of these life-saving medications.”
Hach Rose Schirripa & Cheverie filed this class action suit in 2014, alleging that Celgene had monopolized the market for two drugs, Thalomid and Revlimid, which are primarily used to treat multiple myeloma, a cancer that forms in the blood. Specifically, the plaintiffs alleged that Celgene kept generic versions of these two drugs off the market, in violation of state and federal antitrust laws. Throughout the litigation, the end payor plaintiffs asserted that prices for the two drugs were higher than they would have been in a competitive market.
The parties agreed to resolve the case following the close of discovery and during the pendency of the plaintiffs’ motion to certify the class. Any person or entity that paid for some or all of the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee, for use by themselves, their families, or their members, employees, insureds, participants, or beneficiaries, will be invited to file a claim to participate in the settlement.
Hach Rose Schirripa & Cheverie attorneys working on this case include Frank Schirripa, Daniel Rehns, Seth Pavsner and Kathryn Hettler. The other lead counsel in the case were Hausfeld LLP and Block & Leviton LLP.
For further information or to arrange interviews please contact:
Frank Schirripafschirripa@hrsclaw.com212-213-8311
About Hach Rose Schirripa & Cheverie
Hach Rose Schirripa & Cheverie LLP specializes in the fields of antitrust, securities, corporate governance and consumer protection litigation. Over the past twenty years, the firm’s attorneys have established themselves as leading representatives of investor and consumer rights in these areas. The firms’ attorneys have successfully litigated complex class actions in both state and federal courts through the United States and are committed to protecting consumers’ rights, investors’ assets and victims of corporate wrongdoing. For more information about the firm, please visit www.hrsclaw.com.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions